Neurocrine Biosciences' chief corporate affairs officer sells shares worth $208,387

David W. Boyer, Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently executed several stock transactions, as disclosed in a recent SEC filing. The company, currently valued at $11.4 billion, has seen its stock decline 15.7% year-to-date. On February 13, Boyer sold a total of 1,785 shares of Neurocrine Biosciences' common stock. The sales, conducted through a pre-established trading plan, fetched approximately $208,387.

The sales were made in two batches: 955 shares were sold at a weighted average price of $116.7939 per share, totaling $111,538, and 830 shares at an average price of $116.6857 per share, amounting to $96,849. These transactions were part of a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stocks. According to InvestingPro data, the stock is trading near its 52-week low, with strong financial health metrics including a current ratio of 3.4.

In addition to the sales, Boyer acquired 3,352 shares through stock option exercises at no cost, increasing his direct ownership to 3,565 shares post-transaction. These acquisitions were made through the vesting of restricted stock units.

Neurocrine Biosciences, headquartered in San Diego, focuses on developing treatments for neurological and endocrine-related disorders.

In other recent news, Neurocrine Biosciences has been the subject of several analyst adjustments following its fourth-quarter sales report and 2025 revenue guidance. Deutsche Bank (ETR:DBKGn) initiated coverage on Neurocrine Biosciences with a Hold rating and a price target of $138, citing the current valuation of the company's stock and the potential of its Ingrezza and Crensessity treatments. UBS, however, lowered its price target for Neurocrine from $176 to $154 but maintained a Buy rating, reflecting a more conservative growth trajectory for Ingrezza.

Similarly, Guggenheim and H.C. Wainwright also adjusted their price targets for Neurocrine to $163 and $185 respectively, while maintaining Buy ratings. These adjustments were driven by the company's recent sales report, which showed Ingrezza sales slightly below consensus estimates and a miss on earnings expectations. Despite these challenges, both firms expressed confidence in the long-term potential of Neurocrine's products, including Crenessity.

Furthermore, the company's pipeline development was noted, with potential treatments such as NBI-568 for schizophrenia and osavampator for major depressive disorder moving into Phase 3 development. These are recent developments that investors should consider as they evaluate the prospects of Neurocrine Biosciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.